BRPI0518547A2 - composto, composiÇço farmacÊutica, uso de um composto, e, uso de uma composiÇço farmacÊutica - Google Patents

composto, composiÇço farmacÊutica, uso de um composto, e, uso de uma composiÇço farmacÊutica

Info

Publication number
BRPI0518547A2
BRPI0518547A2 BRPI0518547-5A BRPI0518547A BRPI0518547A2 BR PI0518547 A2 BRPI0518547 A2 BR PI0518547A2 BR PI0518547 A BRPI0518547 A BR PI0518547A BR PI0518547 A2 BRPI0518547 A2 BR PI0518547A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
methods
diastereoisomers
enantiomers
Prior art date
Application number
BRPI0518547-5A
Other languages
English (en)
Inventor
Robert Jacobs
Richard J Schmiesing
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0518547A2 publication Critical patent/BRPI0518547A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO, COMPOSIÇçO FARMACÊUTICA, USO DE UM COMPOSTO, E, USO DE UMA COMPOSIÇçO FARMACÊUTICA. Ligantes do receptor da acetilcolina de fórmula (I) em que D, E e G são descritos no relatório descritivo, diastereoisômeros, enanciômeros, sais farmaceuticamente aceitáveis deste, métodos de preparo, composições farmacêuticas que contém e métodos para usar os mesmos.
BRPI0518547-5A 2004-12-16 2005-12-14 composto, composiÇço farmacÊutica, uso de um composto, e, uso de uma composiÇço farmacÊutica BRPI0518547A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63668004P 2004-12-16 2004-12-16
PCT/SE2005/001919 WO2006065217A1 (en) 2004-12-16 2005-12-14 Nicotinic acetycholine receptor ligands

Publications (1)

Publication Number Publication Date
BRPI0518547A2 true BRPI0518547A2 (pt) 2008-11-25

Family

ID=36588167

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518547-5A BRPI0518547A2 (pt) 2004-12-16 2005-12-14 composto, composiÇço farmacÊutica, uso de um composto, e, uso de uma composiÇço farmacÊutica

Country Status (13)

Country Link
US (1) US20080103170A1 (pt)
EP (1) EP1831212A4 (pt)
JP (1) JP2008524212A (pt)
KR (1) KR20070086273A (pt)
CN (1) CN101119994A (pt)
AU (1) AU2005317235A1 (pt)
BR (1) BRPI0518547A2 (pt)
CA (1) CA2592321A1 (pt)
IL (1) IL183598A0 (pt)
MX (1) MX2007007024A (pt)
NO (1) NO20073547L (pt)
WO (1) WO2006065217A1 (pt)
ZA (1) ZA200705106B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2974365B1 (fr) * 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques
WO2016154434A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of California Selective alpha-7 nicotinic receptor agonists and methods for making and using them
WO2023213739A1 (en) * 2022-05-05 2023-11-09 Philip Morris Products S.A. Nicotinic acetylcholine receptor ligands

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
US5041450A (en) * 1988-06-29 1991-08-20 Research Corporation Technologies, Inc. Treatment of ocular inflammation
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
DE60311853T2 (de) * 2002-09-30 2007-06-21 Neurosearch A/S Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
SE0303075D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 4-substituted imidazoles

Also Published As

Publication number Publication date
WO2006065217A1 (en) 2006-06-22
NO20073547L (no) 2007-08-01
MX2007007024A (es) 2007-07-04
EP1831212A4 (en) 2010-01-13
IL183598A0 (en) 2007-09-20
CN101119994A (zh) 2008-02-06
JP2008524212A (ja) 2008-07-10
AU2005317235A1 (en) 2006-06-22
EP1831212A1 (en) 2007-09-12
US20080103170A1 (en) 2008-05-01
KR20070086273A (ko) 2007-08-27
CA2592321A1 (en) 2006-06-22
ZA200705106B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0518949A2 (pt) composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
AR060755A1 (es) Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv)
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
CR8717A (es) Nuevos compuestos
BRPI0616077B8 (pt) composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
DOP2010000387A (es) Compuestos pirazolicos 436
DK1915150T3 (da) Anvendelse af thienopyridinonderivater som AMPK-aktivatorer og farmaceutiske sammensætninger
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
DOP2006000268A (es) Agentes antibacterianos
AR047928A1 (es) Derivados de tetrahidropiridoindol
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
UY30304A1 (es) Moduladores de mglur5 i
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
BRPI0511999A (pt) compostos como antagonistas de ccr5
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.